Please login to the form below

Pradaxa

This page shows the latest Pradaxa news and features for those working in and with pharma, biotech and healthcare.

Ingelheim’s thrombin inhibitor Pradaxa (dabigatran).

The business case for patient engagement

More notably, Lixiana users are far less likely to promote the drug than Xarelto or Pradaxa users, despite having a similar level of confidence in the drug as Xarelto users and ... significantly more confidence than Pradaxa users.
CHMP backs Lynparza in breast cancer, Dupixent in asthma

So far, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - is the only NOAC on the market with a reversal agent available.
Bad news for Portola as CHMP considers Factor Xa drugs

In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - remains the only new anticoagulant on the market with a reversal agent available.
Xarelto no better than aspirin in secondary stroke study

For years it led the market among NOAC drugs, keeping ahead of Pfizer and Bristol-Myers Squibb’s Eliquis (apixaban) and with Boehringer Ingelheim’s Pradaxa (dabigatran) and Daiichi Sankyo’s
Xarelto beats aspirin for recurrent blood clots

rival NOAC Eliquis (apixaban) from Pfizer and Bristol-Myers Squibb (BMS) with 42.5%, well ahead of third place Pradaxa (dabigatran) from Boehringer Ingelheim and Daiichi Sankyo's new entrant Savaysa

More from news
Approximately 22 fully matching, plus 60 partially matching documents found.

Pharma deals during May 2014

At least the $225m will go some way towards paying for the $650m settlement of the US Pradaxa litigation Boehringer announced in May.
Interview: Allan Hillgrove, Boehringer

So far in 2013 the company has seen continued growth of its next-generation anticoagulant Pradaxa against fierce competition from rival drugs from Bristol-Myers Squibb/Pfizer and Bayer; pledged to ... American College of Cardiology (ACC) to educate
Modern anticoagulants threaten status quo

Dabigatran etexilate. Notwithstanding the initial setback for DTIs, Boehringer Ingelheim (BI) first launched its twice-daily DTI prodrug, dabigatran etexilate (Pradaxa/Pradax), in 2008.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Frontera proud finalists for the 2020 PM Awards

Meanwhile, the agency’s extensive work across multiple Boehringer Ingelheim products including Pradaxa, Spiolto and OFEV were also recognised in Film &Animation (HCPs), Mixed Media Campaign and Sales Aid categories.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Medical Writers > Scientific Directors – Medical Communicatio...: Highly Competitive Salary, Bonus &Benefits

Vaccines writer – career opportunity to move into medcomms from ...: Highly competitive salary

Principal Medical Writer, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

PR/ PA Account Executive (UK Healthcare Industry specialist, cam...: Competitive

Client Services Director, MRNA/ Covid 19, Medical Communications...: Highly competitive salary

HR Manager – Recruitment/ Generalist combined role, Marketing ag...: circa £50K

Scientific Director, MRNA/ Covid 19, Medical Communications, UK: Six figure salary

Senior Account Exec > CSD – Medical Communications – UK, Lond...: Highly Competitive Salary, Bonus &Benefits

Add my company

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Diversity in clinical trials: looking back at our 2021 blogs: In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?: Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:: Securing a future for telehealth with immersive market research insights...

Email:
Password: